238 related articles for article (PubMed ID: 26341737)
1. Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer.
Ali A; Creevey L; Hao Y; McCartan D; O'Gaora P; Hill A; Young L; McIlroy M
Breast Cancer Res; 2015 Sep; 17(1):123. PubMed ID: 26341737
[TBL] [Abstract][Full Text] [Related]
2. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
[TBL] [Abstract][Full Text] [Related]
3. Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells.
Koochekpour S; Lee TJ; Sun Y; Hu S; Grabowski GA; Liu Z; Garay J
J Cell Biochem; 2008 Aug; 104(6):2272-85. PubMed ID: 18481277
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
5. Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy.
Creevey L; Bleach R; Madden SF; Toomey S; Bane FT; Varešlija D; Hill AD; Young LS; McIlroy M
Mol Cancer Ther; 2019 Oct; 18(10):1731-1743. PubMed ID: 31289138
[TBL] [Abstract][Full Text] [Related]
6. Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected].
McIlroy M; McCartan D; Early S; O Gaora P; Pennington S; Hill AD; Young LS
Cancer Res; 2010 Feb; 70(4):1585-94. PubMed ID: 20145129
[TBL] [Abstract][Full Text] [Related]
7. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
8. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
Liu H; Wang J; Zhang M; Xuan Q; Wang Z; Lian X; Zhang Q
Breast Cancer Res Treat; 2017 Nov; 166(1):95-107. PubMed ID: 28730338
[TBL] [Abstract][Full Text] [Related]
9. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death.
Choi HJ; Lui A; Ogony J; Jan R; Sims PJ; Lewis-Wambi J
Breast Cancer Res; 2015 Jan; 17(1):6. PubMed ID: 25588716
[TBL] [Abstract][Full Text] [Related]
10. miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
Bacci M; Giannoni E; Fearns A; Ribas R; Gao Q; Taddei ML; Pintus G; Dowsett M; Isacke CM; Martin LA; Chiarugi P; Morandi A
Cancer Res; 2016 Mar; 76(6):1615-26. PubMed ID: 26795347
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197
[TBL] [Abstract][Full Text] [Related]
14. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
15. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
16. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Jan R; Huang M; Lewis-Wambi J
Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
[TBL] [Abstract][Full Text] [Related]
17. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.
Fiorillo M; Sotgia F; Sisci D; Cappello AR; Lisanti MP
Oncotarget; 2017 Mar; 8(12):20309-20327. PubMed ID: 28411284
[TBL] [Abstract][Full Text] [Related]
19. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
20. The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.
Wong C; Chen S
J Steroid Biochem Mol Biol; 2012 Sep; 131(3-5):83-92. PubMed ID: 22265958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
